Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
Monday, August 19, 2024RedHill Biopharma Ltd a specialty biopharmaceutical company today announced that it plans to implement a ratio change of the Companys American Depositary
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders
Monday, August 19, 2024Bavarian Nordic AS provides an update on plans for securing supply of vaccines to tackle the current mpox outbreak that the Africa Centers for Disease Control
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
Friday, August 16, 2024Silexion Therapeutics Ltd a clinicalstage oncologyfocused biotechnology company and Moringa Acquisition Corp a publiclytraded special purpose acquisition company today announced the completion
Nuntius Therapeutics Announces Collaboration with Taiho Pharmaceutical to Develop Next-Generation mRNA Therapies Using Nuntius’ Proprietary Cell-Specific Delivery Technology
Friday, August 16, 2024Nuntius Therapeutics a biotech company developing transformative mRNA therapies through their advanced delivery technology today announced that they have entered into a collaboration agreement
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
Wednesday, August 14, 2024Renexxion Ireland Limited a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal GI disorders in collaboration with its partner Dr Falk Pharma GmbH Dr Falk Pharma announce dos...
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
Tuesday, August 13, 2024Conduit Pharmaceuticals Inc today announced the selection of initial indications for its lead clinical candidate HK glucokinase activator AZD licensed from AstraZeneca on August
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
Tuesday, August 13, 2024Oragenics Inc a company focused on developing unique intranasal pharmaceuticals for the treatment of neurological disorders today announced its lead candidate for treating concussion ONP successfully completed a study that indicates it does not cause...
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
Monday, August 12, 2024Sandoz the global leader in generic and biosimilar medicines today announced that the US Food and Drug Administration FDA has approved Enzeevu afliberceptabzv mg vial kit and prefilled syringe for intravitreal injection Enzeevu
Flamingo Therapeutics Announces First Patients Dosed in the United Kingdom and Korea in Ongoing Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)
Friday, August 09, 2024Flamingo Therapeutics announced that the PEMDAHN trial has expanded beyond the United States into the UK and Korea Patient enrollment in the USA started in February and now the first patients have been dosed in these new geographies
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Thursday, August 08, 2024Novartis today announced that the US Food and Drug Administration FDA has granted accelerated approval for Fabhalta iptacopan a firstinclass complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin
